Pharvaris N.V.
General ticker "PHVS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Pharvaris N.V. follows the US Stock Market performance with the rate: 52.0%.
Estimated limits based on current volatility of 2.5%: low 28.85$, high 30.32$
Factors to consider:
- Total employees count: 129 (+19.4%) as of 2025
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.06$, 40.03$]
- 2026-12-31 to 2027-12-31 estimated range: [12.12$, 31.56$]
Financial Metrics affecting the PHVS estimates:
- Negative: with PPE of -7.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 89.99 > 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0
- Negative: -0.37 < Inventory ratio change, % of 0
- Negative: negative Industry operating income (median)
Short-term PHVS quotes
Long-term PHVS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €0.00MM | €0.00MM | €0.00MM |
| Operating Expenses | €96.91MM | €145.69MM | €169.82MM |
| Operating Income | €-96.91MM | €-145.69MM | €-169.82MM |
| Non-Operating Income | €-2.91MM | €13.29MM | €-3.89MM |
| R&D Expense | €65.58MM | €98.56MM | €124.48MM |
| Income(Loss) | €-99.83MM | €-132.40MM | €-173.71MM |
| Taxes | €0.00MM | €1.83MM | €0.00MM |
| Net Income(Loss)* | €-100.88MM | €-134.22MM | €-175.70MM |
| Stockholders Equity | €384.05MM | €267.76MM | €271.27MM |
| Assets | €398.69MM | €291.37MM | €301.45MM |
| Operating Cash Flow | €-93.05MM | €-120.13MM | €-137.07MM |
| Capital expenditure | €0.09MM | €0.54MM | €0.16MM |
| Investing Cash Flow | €-0.09MM | €-0.54MM | €-0.16MM |
| Financing Cash Flow | €325.39MM | €2.68MM | €160.61MM |
| Earnings Per Share** | €-2.63 | €-2.48 | €-2.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.